5-(5-methylthiophen-2-yl)-pyridin-2-ylamine | 1110657-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(5-methylthiophen-2-yl)-pyridin-2-ylamine
• 英文别名: 5-(5-Methyl-2-thienyl)-2-pyridinamine；5-(5-methylthiophen-2-yl)pyridin-2-amine
• CAS: 1110657-43-6
• 化学式: C₁₀H₁₀N₂S
• 分子量: 190.269
• InChiKey: IQWHDEIIGHPEQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基噻吩 、 2-氨基-5-溴吡啶 在 PdCl(C₃H₅)(dppb) 、 potassium acetate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 20.0h， 以60%的产率得到5-(5-methylthiophen-2-yl)-pyridin-2-ylamine
  参考文献：
  名称：

  Palladium-catalysed direct arylation of heteroaromatics with functionalised bromopyridines

  摘要：

  The regioselective 5-arylation of a variety of heteroaromatics with functionalised pyridyl bromides using palladium catalyst gives a simple access to functionalised heteroarylated pyridines. The target products were obtained in moderate to good yields using only 1 mol % PdCl(C3H5)(dppb) as the catalyst. Substituents, such as fluoro, acetyl, nitrile, nitro, methoxy or amino on the pyridyl bromide are tolerated. However, the nature of the substituents has an important influence on the yields. Electron-withdrawing substituent favours the reaction; whereas electron-donating are unfavourable. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.06.034

文献信息

• [EN] N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-CYCLYL-3-(CYCLYLCARBONYLAMINOMÉTHYL)BENZAMIDE EN TANT QU'INHIBITEURS DE LA RHO KINASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012006203A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of formula (I) : and pharmaceutically acceptable salts thereof, wherein R1and R2 are various ring systems. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase mediated diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及化合物的公式（I）及其药学上可接受的盐，其中R1和R2是不同的环系统。该发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗Rho激酶介导的疾病和障碍的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• RHO KINASE INHIBITORS
  申请人：Cook Brian Nicholas

  公开号：US20120165322A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物和其药学上可接受的盐，其中R1和R2的定义如本文所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2590950B1

  公开（公告）日：2014-10-15
• Palladium-catalysed direct arylation of heteroaromatics with functionalised bromopyridines
  作者：Souhila Bensaid、Henri Doucet

  DOI：10.1016/j.tet.2012.06.034

  日期：2012.9

  The regioselective 5-arylation of a variety of heteroaromatics with functionalised pyridyl bromides using palladium catalyst gives a simple access to functionalised heteroarylated pyridines. The target products were obtained in moderate to good yields using only 1 mol % PdCl(C3H5)(dppb) as the catalyst. Substituents, such as fluoro, acetyl, nitrile, nitro, methoxy or amino on the pyridyl bromide are tolerated. However, the nature of the substituents has an important influence on the yields. Electron-withdrawing substituent favours the reaction; whereas electron-donating are unfavourable. (C) 2012 Elsevier Ltd. All rights reserved.